MedDataX Logo

Endometrial Advancement After Rec or u-HCG Triggering

NCT ID: NCT00953628

Last Updated: 2015-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Biopsies of endometrium were taken in different groups Pregnancy rates were compared among defferent groups

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

o Group A=uHCG ovul trig

HCG for triggering

Group Type ACTIVE_COMPARATOR

10000 IU urinary HCG

Intervention Type DRUG

bolus 10000 units for ovulation triggering

o Group B=recHCG ovul trig

recombinant HCG for triggering

Group Type EXPERIMENTAL

250 mcg recombinant HCG

Intervention Type DRUG

bolus 250 mcg for ovulation triggering in IVF patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

10000 IU urinary HCG

bolus 10000 units for ovulation triggering

Intervention Type DRUG

250 mcg recombinant HCG

bolus 250 mcg for ovulation triggering in IVF patients

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pregnyl Ovitrelle

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Less than 36 years old
* Male or tubal infertility
* FSH\<12 on day 3

Exclusion Criteria

* Endometriosis stage 3 \& 4
Minimum Eligible Age

20 Years

Maximum Eligible Age

36 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Serono International SA

INDUSTRY

Sponsor Role collaborator

Universitair Ziekenhuis Brussel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Papanikolaou Evangelos

Lecturer Aristotle University Greece

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Devroey, Professor

Role: STUDY_DIRECTOR

Professor or OB-GYN

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Reproductive Medicine, UZ Brussel

Brussels, Jette, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

recHCG001

Identifier Type: -

Identifier Source: org_study_id